Baysient Announces the Release of a Digital TDM App for Personalized Infliximab Dosing

Its new technique, which builds on the strength and accuracy of the iDose platform, is easier to use and faster while still delivering findings consistent with the iDose platform.

FREMONT, CA: T3 Time To Target, a new web-based tool from Baysient LLC, is designed for the simple precision dosage of Infliximab. The groundbreaking nomogram software uses accurate patient clinical parameters and a measured trough concentration to determine a patient's half-life, predicting how long it'll take for each patient's medication concentration to fall below a target, with an elegant and user-friendly interface.

"This new app can be a game-changer for caregivers along the entire spectrum of IBD," noted Dr. Diane Mould, Founder and Chief Technical Officer of Baysient LLC.

Its new technique, which builds on the strength and accuracy of the iDose platform, is easier to use and faster while still delivering findings consistent with the iDose platform.

"Infliximab has traditionally had a higher rate of drug failure. Drug companies often provide therapeutic drug monitoring tests, but most physicians don't know how to make use of the data. And, it can be a nightmare in clinical trial settings when switching from Infliximab to another monoclonal antibody. This new app can help quickly deal with all of that — it will enable the caregiver to quickly find the proper maintenance dose and dose interval as well as the proper washout period for a given patient by taking into account the unique, individual factors that impact the patient's response to therapy," said Dr. Mould.

About Baysient:

Baysient LLC creates SaaS, cloud-based software that provides medical professionals with a full line of individual dosage-determination solutions to give tailored therapies for patients with better outcomes. Baysient's revolutionary software, iDose, and T3 enable individualized and improved clinical development for inflammatory diseases like inflammatory bowel disease (IBD), Crohn's disease (CD), rheumatoid arthritis (RA), and more by working with gastroenterologists to safely reduce the incidence of anti-drug antibodies during maintenance.